@article {4892, title = {Evaluation and Application of Donors with Primary Central Nervous System Tumors}, volume = {33}, year = {2019}, month = {Oct}, pages = {e13677}, abstract = {Background: This study aimed to explore the safety of donors with primary central nervous system tumors for kidney and liver transplantations. Methodology: Clinical data of 29 donors with primary CNS tumors in January 2007 to December 2017, as well as the follow-up data of 16 liver transplant recipients and 46 kidney transplant recipients, were analyzed. According to the risk factors, the high-risk group was classified as Group 1, the low-risk factors were classified as Group 2, and the unknown risk group was classified as Group 3. The incidence of donor-transmitted CNS tumors was calculated and compared. Results: The duration from the diagnosis of 29 donors to donation was 5.67 {\textpm} 6.36 months. None of the liver and kidney transplant recipients who were followed up had tumor metastasis. Although the mean survival time of Group 1 was lower than that of Group 2 and Group 3, the Kaplan-Meier curve showed no significant difference in survival time. Conclusion: No obvious difference was observed between high-risk and low-risk and unknown risk CNS tumors in terms of the survival rate of transplants and tumor metastasis rate. High-risk CNS tumor donors can be used with the informed consent of recipients after a full evaluation.}, author = {Wu, JH and Qiao, PF and Sun, XY and Dong, JH and Liao, JX and Liu, XY and Gao, Z and Lan, LG and Li, HB and Su, QD} }